Advertisement
Screener

Nektar Therapeutics (NKTR) Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

Nektar Therapeutics Comprehensive Income

Nektar Therapeutics (NKTR) reported Comprehensive Income of -$41.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-14

  • Nektar Therapeutics comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$41.34M.
  • Nektar Therapeutics comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$45.95M.
  • Nektar Therapeutics comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$36.12M, a 618.42% decline year-over-year.
  • Nektar Therapeutics comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$35.45M.
  • Nektar Therapeutics comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$164.12M.
  • Nektar Therapeutics comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$118.98M.
  • Nektar Therapeutics comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$269.07M.
  • Nektar Therapeutics comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$370.95M.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month
2026-06-30-$41.34M
10-Q · filed 2026-08-14
-$87.30M
10-Q · filed 2026-08-14
-$123.42M
derived: sum of 3 quarters · filed 2026-08-14
-$158.87M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31-$45.95M
10-Q · filed 2026-08-14
-$82.07M
derived: sum of 2 quarters · filed 2026-08-14
-$117.53M
derived: sum of 3 quarters · filed 2026-08-14
-$159.17M
derived: sum of 4 quarters · filed 2026-08-14
2025-12-31-$36.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13
-$71.57M
derived: sum of 2 quarters · filed 2026-03-13
-$113.22M
derived: sum of 3 quarters · filed 2026-08-14
-$164.12M
10-K · filed 2026-03-13
2025-09-30-$35.45M
10-Q · filed 2025-11-07
-$77.10M
derived: sum of 2 quarters · filed 2026-08-14
-$128.00M
10-Q · filed 2025-11-07
-$121.03M
derived: sum of 4 quarters · filed 2026-08-14
2025-06-30-$41.65M
10-Q · filed 2026-08-14
-$92.55M
10-Q · filed 2026-08-14
-$85.58M
derived: sum of 3 quarters · filed 2026-08-14
-$121.79M
derived: sum of 4 quarters · filed 2026-08-14
2025-03-31-$50.90M
10-Q · filed 2026-08-14
-$43.94M
derived: sum of 2 quarters · filed 2026-08-14
-$80.14M
derived: sum of 3 quarters · filed 2026-08-14
-$132.60M
derived: sum of 4 quarters · filed 2026-08-14
2024-12-31$6.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13
-$29.24M
derived: sum of 2 quarters · filed 2026-03-13
-$81.69M
derived: sum of 3 quarters · filed 2026-03-13
-$118.98M
10-K · filed 2026-03-13
2024-09-30-$36.21M
10-Q · filed 2025-11-07
-$88.66M
derived: sum of 2 quarters · filed 2025-11-07
-$125.95M
10-Q · filed 2025-11-07
-$161.59M
derived: sum of 4 quarters · filed 2025-11-07
2024-06-30-$52.45M
10-Q · filed 2025-11-07
-$89.74M
10-Q · filed 2025-08-08
-$125.39M
derived: sum of 3 quarters · filed 2025-11-07
-$171.13M
derived: sum of 4 quarters · filed 2025-11-07
2024-03-31-$37.28M
10-Q · filed 2025-11-07
-$72.93M
derived: sum of 2 quarters · filed 2025-11-07
-$118.67M
derived: sum of 3 quarters · filed 2025-11-07
-$170.56M
derived: sum of 4 quarters · filed 2025-11-07
2023-12-31-$35.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14
-$81.39M
derived: sum of 2 quarters · filed 2025-03-14
-$133.28M
derived: sum of 3 quarters · filed 2025-03-14
-$269.07M
10-K · filed 2025-03-14
2023-09-30-$45.74M
10-Q · filed 2024-11-08
-$97.63M
derived: sum of 2 quarters · filed 2024-11-08
-$233.42M
10-Q · filed 2024-11-08
-$291.85M
derived: sum of 4 quarters · filed 2024-11-08
2023-06-30-$51.89M
10-Q · filed 2024-11-08
-$187.68M
10-Q · filed 2024-08-09
-$246.11M
derived: sum of 3 quarters · filed 2024-11-08
-$305.14M
derived: sum of 4 quarters · filed 2024-11-08
2023-03-31-$135.79M
10-Q · filed 2024-11-08
-$194.22M
derived: sum of 2 quarters · filed 2024-11-08
-$253.25M
derived: sum of 3 quarters · filed 2024-11-08
-$413.97M
derived: sum of 4 quarters · filed 2024-11-08
2022-12-31-$58.43M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05
-$117.45M
derived: sum of 2 quarters · filed 2024-03-05
-$278.18M
derived: sum of 3 quarters · filed 2024-03-05
-$370.95M
10-K · filed 2024-03-05
2022-09-30-$59.03M
10-Q · filed 2023-11-08
-$219.75M
derived: sum of 2 quarters · filed 2023-11-08
-$312.52M
10-Q · filed 2023-11-08
-$458.76M
derived: sum of 4 quarters · filed 2024-03-05
2022-06-30-$160.73M
10-Q · filed 2023-11-08
-$253.50M
10-Q · filed 2023-08-09
-$399.73M
derived: sum of 3 quarters · filed 2024-03-05
-$529.60M
derived: sum of 4 quarters · filed 2024-03-05
2022-03-31-$92.77M
10-Q · filed 2023-11-08
-$239.01M
derived: sum of 2 quarters · filed 2024-03-05
-$368.88M
derived: sum of 3 quarters · filed 2024-03-05
-$494.67M
derived: sum of 4 quarters · filed 2024-03-05
2021-12-31-$146.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05
-$276.11M
derived: sum of 2 quarters · filed 2024-03-05
-$401.91M
derived: sum of 3 quarters · filed 2024-03-05
-$525.70M
10-K · filed 2024-03-05
2021-09-30-$129.87M
10-Q · filed 2022-11-04
-$255.67M
derived: sum of 2 quarters · filed 2022-11-04
-$379.46M
10-Q · filed 2022-11-04
-$497.88M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30-$125.80M
10-Q · filed 2022-11-04
-$249.59M
10-Q · filed 2022-08-05
-$368.01M
derived: sum of 3 quarters · filed 2023-02-28
-$478.39M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31-$123.79M
10-Q · filed 2022-11-04
-$242.21M
derived: sum of 2 quarters · filed 2023-02-28
-$352.59M
derived: sum of 3 quarters · filed 2023-02-28
-$425.00M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31-$118.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
-$228.80M
derived: sum of 2 quarters · filed 2023-02-28
-$301.21M
derived: sum of 3 quarters · filed 2023-02-28
-$445.73M
10-K · filed 2023-02-28
2020-09-30-$110.38M
10-Q · filed 2021-11-05
-$182.79M
derived: sum of 2 quarters · filed 2021-11-05
-$327.31M
10-Q · filed 2021-11-05
-$440.57M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30-$72.41M
10-Q · filed 2021-11-05
-$216.93M
10-Q · filed 2021-08-06
-$330.19M
derived: sum of 3 quarters · filed 2022-03-01
-$429.39M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31-$144.52M
10-Q · filed 2021-11-05
-$257.78M
derived: sum of 2 quarters · filed 2022-03-01
-$356.99M
derived: sum of 3 quarters · filed 2022-03-01
-$464.97M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31-$113.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
-$212.46M
derived: sum of 2 quarters · filed 2022-03-01
-$320.44M
derived: sum of 3 quarters · filed 2022-03-01
-$435.36M
10-K · filed 2022-03-01
2019-09-30-$99.21M
10-Q · filed 2020-11-06
-$207.19M
derived: sum of 2 quarters · filed 2020-11-06
-$322.10M
10-Q · filed 2020-11-06
-$421.25M
derived: sum of 4 quarters · filed 2021-02-26
2019-06-30-$107.98M
10-Q · filed 2020-11-06
-$222.89M
10-Q · filed 2020-08-07
-$322.04M
derived: sum of 3 quarters · filed 2021-02-26
-$419.56M
derived: sum of 4 quarters · filed 2021-02-26
2019-03-31-$114.91M
10-Q · filed 2020-11-06
-$214.06M
derived: sum of 2 quarters · filed 2021-02-26
-$311.58M
derived: sum of 3 quarters · filed 2021-02-26
$658.67M
derived: sum of 4 quarters · filed 2021-02-26
2018-12-31-$99.15M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26
-$196.67M
derived: sum of 2 quarters · filed 2021-02-26
$773.59M
derived: sum of 3 quarters · filed 2021-02-26
$677.11M
10-K · filed 2021-02-26
2018-09-30-$97.52M
10-Q · filed 2019-11-07
$872.74M
derived: sum of 2 quarters · filed 2019-11-07
$776.26M
10-Q · filed 2019-11-07
$742.23M
derived: sum of 4 quarters · filed 2020-02-28
2018-06-30$970.25M
10-Q · filed 2019-08-09
$873.78M
10-Q · filed 2019-08-09
$839.75M
derived: sum of 3 quarters · filed 2020-02-28
$900.37M
derived: sum of 4 quarters · filed 2020-02-28
2018-03-31-$96.48M
10-Q · filed 2019-05-09
-$130.51M
derived: sum of 2 quarters · filed 2020-02-28
-$69.88M
derived: sum of 3 quarters · filed 2020-02-28
-$129.56M
derived: sum of 4 quarters · filed 2020-02-28
2017-12-31-$34.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28
$26.60M
derived: sum of 2 quarters · filed 2020-02-28
-$33.09M
derived: sum of 3 quarters · filed 2020-02-28
-$96.44M
10-K · filed 2020-02-28
2017-09-30$60.63M
10-Q · filed 2018-11-08
$942.00K
derived: sum of 2 quarters · filed 2018-11-08
-$62.41M
10-Q · filed 2018-11-08
-$105.01M
derived: sum of 4 quarters · filed 2019-03-01
2017-06-30-$59.68M
10-Q · filed 2018-08-09
-$123.04M
10-Q · filed 2018-08-09
-$165.64M
derived: sum of 3 quarters · filed 2019-03-01
-$208.80M
derived: sum of 4 quarters · filed 2019-03-01
2017-03-31-$63.35M
10-Q · filed 2018-05-10
-$105.95M
derived: sum of 2 quarters · filed 2019-03-01
-$149.12M
derived: sum of 3 quarters · filed 2019-03-01
-$197.91M
derived: sum of 4 quarters · filed 2019-03-01
2016-12-31-$42.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01
-$85.77M
derived: sum of 2 quarters · filed 2019-03-01
-$134.55M
derived: sum of 3 quarters · filed 2019-03-01
-$153.72M
10-K · filed 2019-03-01
2016-09-30-$43.17M
10-Q · filed 2017-11-08
-$91.95M
derived: sum of 2 quarters · filed 2017-11-08
-$111.12M
10-Q · filed 2017-11-08
-$165.60M
derived: sum of 4 quarters · filed 2018-03-01
2016-06-30-$48.79M
10-Q · filed 2017-08-09
-$67.95M
10-Q · filed 2017-08-09
-$122.44M
derived: sum of 3 quarters · filed 2018-03-01
-$130.96M
derived: sum of 4 quarters · filed 2018-03-01
2016-03-31-$19.16M
10-Q · filed 2017-05-10
-$73.65M
derived: sum of 2 quarters · filed 2018-03-01
-$82.17M
derived: sum of 3 quarters · filed 2018-03-01
-$135.05M
derived: sum of 4 quarters · filed 2018-03-01
2015-12-31-$54.49M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01
-$63.01M
derived: sum of 2 quarters · filed 2018-03-01
-$115.89M
derived: sum of 3 quarters · filed 2018-03-01
-$81.78M
10-K · filed 2018-03-01
2015-09-30-$8.53M
10-Q · filed 2016-11-04
-$61.41M
derived: sum of 2 quarters · filed 2016-11-04
-$27.29M
10-Q · filed 2016-11-04
-$73.37M
derived: sum of 4 quarters · filed 2017-03-01
2015-06-30-$52.88M
10-Q · filed 2016-08-04
-$18.77M
10-Q · filed 2016-08-04
-$64.84M
derived: sum of 3 quarters · filed 2017-03-01
$5.47M
derived: sum of 4 quarters · filed 2017-03-01
2015-03-31$34.11M
10-Q · filed 2016-05-04
-$11.96M
derived: sum of 2 quarters · filed 2017-03-01
$58.35M
derived: sum of 3 quarters · filed 2017-03-01
$25.77M
derived: sum of 4 quarters · filed 2017-03-01
2014-12-31-$46.07M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
$24.24M
derived: sum of 2 quarters · filed 2017-03-01
-$8.34M
derived: sum of 3 quarters · filed 2017-03-01
-$54.30M
10-K · filed 2017-03-01
2014-09-30$70.31M
10-Q · filed 2015-11-06
$37.73M
derived: sum of 2 quarters · filed 2015-11-06
-$8.23M
10-Q · filed 2015-11-06
-$55.38M
derived: sum of 4 quarters · filed 2016-02-29
2014-06-30-$32.58M
10-Q · filed 2015-08-06
-$78.54M
10-Q · filed 2015-08-06
-$125.69M
derived: sum of 3 quarters · filed 2016-02-29
-$142.59M
derived: sum of 4 quarters · filed 2016-02-29
2014-03-31-$45.96M
10-Q · filed 2015-05-01
-$93.11M
derived: sum of 2 quarters · filed 2016-02-29
-$110.01M
derived: sum of 3 quarters · filed 2016-02-29
-$153.70M
derived: sum of 4 quarters · filed 2016-02-29
2013-12-31-$47.15M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
-$64.05M
derived: sum of 2 quarters · filed 2016-02-29
-$107.74M
derived: sum of 3 quarters · filed 2016-02-29
-$162.84M
10-K · filed 2016-02-29
2013-09-30-$16.90M
10-Q · filed 2014-11-07
-$60.59M
derived: sum of 2 quarters · filed 2014-11-07
-$115.69M
10-Q · filed 2014-11-07
-$169.12M
derived: sum of 4 quarters · filed 2015-02-26
2013-06-30-$43.69M
10-Q · filed 2014-08-01
-$98.79M
10-Q · filed 2014-08-01
-$152.23M
derived: sum of 3 quarters · filed 2015-02-26
-$195.00M
derived: sum of 4 quarters · filed 2015-02-26
2013-03-31-$55.10M
10-Q · filed 2014-05-08
-$108.54M
derived: sum of 2 quarters · filed 2015-02-26
-$151.31M
derived: sum of 3 quarters · filed 2015-02-26
-$186.17M
derived: sum of 4 quarters · filed 2015-02-26
2012-12-31-$53.44M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26
-$96.21M
derived: sum of 2 quarters · filed 2015-02-26
-$131.07M
derived: sum of 3 quarters · filed 2015-02-26
-$171.11M
10-K · filed 2015-02-26
2012-09-30-$42.77M
10-Q · filed 2013-11-07
-$77.63M
derived: sum of 2 quarters · filed 2013-11-07
-$117.67M
10-Q · filed 2013-11-07
-$155.28M
derived: sum of 4 quarters · filed 2014-02-27
2012-06-30-$34.86M
10-Q · filed 2013-08-09
-$74.90M
10-Q · filed 2013-08-09
-$112.51M
derived: sum of 3 quarters · filed 2014-02-27
-$138.33M
derived: sum of 4 quarters · filed 2014-02-27
2012-03-31-$40.04M
10-Q · filed 2013-05-09
-$77.65M
derived: sum of 2 quarters · filed 2014-02-27
-$103.47M
derived: sum of 3 quarters · filed 2014-02-27
-$139.90M
derived: sum of 4 quarters · filed 2014-02-27
2011-12-31-$37.61M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27
-$63.43M
derived: sum of 2 quarters · filed 2014-02-27
-$99.86M
derived: sum of 3 quarters · filed 2014-02-27
-$136.05M
10-K · filed 2014-02-27
2011-09-30-$25.82M
10-Q · filed 2012-11-09
-$62.25M
derived: sum of 2 quarters · filed 2012-11-09
-$98.44M
10-Q · filed 2012-11-09
2011-06-30-$36.43M
10-Q · filed 2012-08-09
-$72.62M
10-Q · filed 2012-08-09
2011-03-31-$36.18M
10-Q · filed 2012-05-04
2010-12-31-$37.99M
10-K · filed 2013-03-01
2009-12-31-$102.93M
10-K · filed 2012-02-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
UroGen Pharma Ltd. (URGN)$2.015B-18.42
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
Generate Biomedicines, Inc. (GENB)United States$2.052B
Biohaven Ltd. (BHVN)United States$1.990B-3.83
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Braveheart Bio, Inc. (BRVE)United States$2.106B
Sarepta Therapeutics, Inc. (SRPT)United States$1.941B-13.89